Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

286

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Vaccines, Pneumococcal
Interventions
BIOLOGICAL

13-valent Pneumococcal Conjugate Vaccine

Single 0.5 mL dose given at 2, 3, 4, and 12 months of age

BIOLOGICAL

7vPnC

Single 0.5 mL dose given at 2, 3, 4 and 12 months of age

BIOLOGICAL

Pediacel

concommitant vaccine, both at arm 1 and at arm 2, at 2 months, 3 months and 4 months of age

BIOLOGICAL

NeisVac-C

concomittant vaccine, both at arm 1 and at arm 2, at 2 months and 4 months of age

BIOLOGICAL

Menitorix

concomitant vaccine, both at arm 1 and at arm 2, at 12 months of age

Trial Locations (11)

CV9 1EU

Atherstone

BT19 1NB

Bangor

BS2 8AE

Bristol

BT41 3AE

Co Antrim

CV6 4DD

Coventry

CB7 4HF

Ely

SW17 ORE

London

OX3 9DU

Oxford

PL5 3JB

Plymouth

SO16 6YD

Southampton

BS22 6AJ

Weston-super-Mare

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00384059 - Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants | Biotech Hunter | Biotech Hunter